Copyright
©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1190-1199
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1190
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1190
Figure 1 Kaplan-Meier analysis.
A: Hepatocellular carcinoma (HCC) recurrence/occurrence after direct-acting antiviral (DAA) treatment of patients with (solid line) and without (dotted line) a history of HCC; B: Kaplan-Meier analysis of HCC events after DAA treatment in patients with 1 (solid line), 2 (dotted line), and ≥ 3 (dashed line) HCC events before DAA treatment. Numbers in parenthesis = 95% confidence interval. NR: Not reached; RFS: Recurrence-free survival; CI: Confidence interval; HCC: Hepatocellular carcinoma.
- Citation: Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199
- URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1190.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1190